THE EFFICACY OF QUETIAPINE XR AS AN ADJUNCTIVE THERAPY
TO DULOXETINE IN DEPRESSED PATIENTS WITH INADEQUATE
RESPONSE TO MONOTHERAPY
THEODOR MOICA 1,2, IOSIF GABOS GRECU 1,2*, DANIELA SABĂU 1,2, SIMONA SZASZ 2, MARIETA GABOS GRECU 1,2, SORINA MOICA 3, ALEXANDRA GROSAN 2, FLORIN BUICU 2
1Psychiatric Clinic I, Târgu Mureş, Romania
2University of Medicine and Pharmacy, Târgu Mureş, Romania
3“Petru Maior” University, Târgu Mureş, Romania
*corresponding author: gabos@orizont.net
Download Full Article

Abstract:
The objective of the study was to demonstrate the efficacy of quetiapine XR (extended release) used as an augmentation
treatment to duloxetine, in patients with major depressive disorder, with inadequate response to monotherapy. In this 8 weeks
prospective study, the efficacy of quetiapine XR used as an augmentation treatment was evaluated using the Hamilton Rating
Scale for Depression (HAM-D17), on two groups of patients: group A - patients with incomplete response, that used
quetiapine XR 150 mg daily as augmentation therapy in addition to duloxetine and group B - patients with incomplete
response who continued the antidepressant monotherapy. We evaluated the levels of depression at baseline (week 0) and at
the end of the study (8th week) for 72 patients. According to HAM-D scores, the level of depression for group A at week 0
(baseline) was M = 22.17 ± 3.23 and after 8 weeks of treatment M = 8.58 ± 3.74. In group B at week 0 (baseline) the level of
depression was M = 24.61 ± 4.19, and M = 18.22 ± 7.78 after 8 weeks of treatment. The patients’ scores between the studied
groups were significantly different after 8 weeks of treatment. Quetiapine XR 150 mg daily may be effective as an
augmentation treatment to duloxetine in patients with major depressive disorder, major depressive episode, single or
recurrent, without psychotic symptoms, with inadequate response to monotherapy.

Top